---
document_datetime: 2023-09-21 20:25:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_en.pdf
document_name: seffalair-spiromax-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9093767
conversion_datetime: 2025-12-26 17:46:32.171036
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name    | Strength          | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size                 |
|------------------|--------------------|-------------------|-----------------------|---------------------------|-----------------------|---------------------------|
| EU/1/21/1533/001 | Seffalair Spiromax | 12.75 µg / 100 µg | Inhalation powder     | Inhalation use            | Inhaler (ABS/PE/PP)   | 1 inhaler (60 doses)      |
| EU/1/21/1533/002 | Seffalair Spiromax | 12.75 µg / 100 µg | Inhalation powder     | Inhalation use            | Inhaler (ABS/PE/PP)   | 3 inhalers (3 x 60 doses) |
| EU/1/21/1533/003 | Seffalair Spiromax | 12.75 µg / 202 µg | Inhalation powder     | Inhalation use            | Inhaler (ABS/PE/PP)   | 1 inhaler (60 doses)      |
| EU/1/21/1533/004 | Seffalair Spiromax | 12.75 µg / 202 µg | Inhalation powder     | Inhalation use            | Inhaler (ABS/PE/PP)   | 3 inhalers (3 x 60 doses) |